A Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Hormone Therapy

Official Title: “An Open-label Phase IIa, Non-randomised, Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy”

The purpose of the study is to investigate if multiple (up to four) intravenous injections of Alpharadin have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for endocrine therapy. In addition the safety of Alpharadin will be assessed.

Intervention(s) in this Clinical Trial

• Drug: Radium-223 chloride (Alpharadin)
  • A maximum of 4 intravenous injections of Alpharadin separated by an interval of 4 weeks. Fixed activity doses of 50 kBq/kg b.w.

Arms, Groups and Cohorts in this Clinical Trial

• Other: A
  • A maximum of 4 intravenous injections of Alpharadin, separated by an interval of 4 weeks. Activity doses of 50 kBq/kg b.w.

Primary Measures

• Changes in bone markers (urine levels of NTX (uNTX) and bone-alkaline phosphatase (ALP)
  • Time Frame: 16 weeks
    Safety Issue?: No

Secondary Measures

• All safety data, including adverse events, changes in laboratory variables, vitals signs, physical examination, late toxicity
  • Time Frame: 1 year
    Safety Issue?: Yes
• Biochemical markers (additional bone markers and CA15.3)
  • Time Frame: 16 weeks
    Safety Issue?: No
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
  • Time Frame: 1 year
    Safety Issue?: No
• Pain
  • Time Frame: 1 year
    Safety Issue?: No

Inclusion Criteria:

• 1. Female, and either post-menopausal (cessation of menses for more than 1 year) or surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy) or in therapy-induced premature menopause with LHRH agonists. If of childbearing potential the result of a urine human chorionic gonadotropin pregnancy test, performed on the same day as and with the result known before study drug administration, must be negative.
• 2. Histological or cytological evidence of primary breast cancer.
• 3. Bone dominant disease (with or without metastases in soft tissue, lymph nodes and/or skin) with at least one non-irradiated bone metastasis on planar bone scintigraphy/SPECT ± CT within previous the 12 weeks.
• 4. Patient has unequivocally progressed on endocrine therapy and further benefit from endocrine therapy is considered unlikely (progression must be documented based on imaging and/or other clinically relevant information).
• 5. Patient has been on bisphosphonate therapy for at least 3 months prior to treatment start and no change to bisphosphonate therapy is expected during the treatment phase of the study, or patient is not being treated with bisphosphonates, and such treatment is not planned to start during the treatment period.
• 6. Latest endocrine therapy stopped at least 2 weeks prior to treatment start.
• 7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 - 2.
• 8. Life expectancy ≥6 months.
• 9. Patient fulfils the following laboratory requirements:
• White Blood Cell Count (WBC) ≥3,000/mm3
• Absolute Neutrophil Count (ANC) ≥1,500/mm3
• Platelet (PLT) count ≥100,000/mm3
• Haemoglobin (HGB) ≥9 g/dl
• Bilirubin ≤2.0 mg/dl
• Aspartate aminotransferase (AST) and Alkaline aminotransferase (ALT) ≤3 times upper institutional limit of the normal range
• Serum creatinine ≤2.0 mg/dl
• 10. Patient must be able and willing to sign an informed consent form indicating that she is aware of the investigational nature of this study in keeping with the policies of the institution, and must have provided written authorisation for use and disclosure of protected health information.
• 11. Patient must be willing and able to comply with the protocol and agree to return to the hospital for follow-up visits and examination.

Exclusion Criteria:

• 1. Received an investigational drug within 4 weeks prior to the administration of Alpharadin, or is scheduled to receive one during the treatment period.
• 2. Received chemotherapy, immunotherapy, or external beam radiation therapy within the last 4 weeks prior to administration of study drug, or has not recovered from acute
• ARs as a result of such therapy.
• 3. Is likely to require chemotherapy or immunotherapy within the 16 weeks treatment period.
• 4. Presence of imminent or established spinal cord compression based on clinical findings and/or MRI.
• 5. Presence of other currently active (relapse within the last 3 years) malignancy (except non melanoma skin cancer) that are not breast cancer metastases.
• 6. Presence of unequivocal visceral metastases requiring chemotherapy treatment in the next 6 months, based on Investigator's judgement. Brain metastases are allowed only if well controlled and if not associated with symptoms. Treatment for brain metastasis should have been completed at least 8 weeks prior to treatment start.
• 7. Patients with any other serious illness or medical condition, such as:
• any uncontrolled infection
• clinical heart failure severe enough to cause marked limitation of activity, and who is only comfortable at rest; or heart failure more severe than this (NYHA
• Heart Failure Class III or IV)
• Crohn's disease or ulcerative colitis
• Bone marrow myelodysplasia
• Unmanageable faecal incontinence

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Algeta ASA Industry

Overall Clinical Trial Officials and Contacts

Robert E Coleman, MD Principal Investigator Weston Park Hospital, Cancer Research Centre, Academic Unit of Clinical Oncology  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT01070485

Study ID Number: BC1-09

ClinicalTrials.gov Identifier: NCT01070485

Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products